Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples.
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Azacitidine
/ pharmacology
Cell Cycle
/ drug effects
Cell Differentiation
/ drug effects
Cell Line, Tumor
Curcumin
/ pharmacology
Drug Synergism
Female
Humans
Leukemia, Myeloid
/ genetics
Male
Myelodysplastic Syndromes
/ genetics
Myelodysplastic syndromes
acute myeloid leukemia
azacitidine
curcumin
synergistic activity
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
07
2019
revised:
25
07
2019
accepted:
26
07
2019
entrez:
15
9
2019
pubmed:
15
9
2019
medline:
27
9
2019
Statut:
ppublish
Résumé
Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples. A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy.
MATERIALS AND METHODS
METHODS
We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients.
RESULTS
RESULTS
The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples.
CONCLUSION
CONCLUSIONS
A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.
Identifiants
pubmed: 31519576
pii: 39/9/4757
doi: 10.21873/anticanres.13659
doi:
Substances chimiques
Antineoplastic Agents
0
Curcumin
IT942ZTH98
Azacitidine
M801H13NRU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4757-4766Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.